AV-951(Tivozanib) is an orally bioavailable potent VEGFR-1, 2 and 3, cKit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.AV-951(Tivozanib) has potential antiangiogenic and antineoplastic activities. AV-951(Tivozanib) inhibits c-Kit and PDGFR at 10-times higher concentrations. AV-951(Tivozanib) is a novel oral quinoline urea derivative. Preclinical data indicate that AV-951 blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo. Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients. AV-951(Tivozanib) is under early clinical investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients.

June 21, 2017

prudect name : AV-951(Tivozanib) is an orally bioavailable potent VEGFR-1, 2 and 3, cKit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.AV-951(Tivozanib) has potential antiangiogenic and antineoplastic activities. AV-951(Tivozanib) inhibits c-Kit and PDGFR at 10-times higher concentrations. AV-951(Tivozanib) is a novel oral quinoline urea derivative. Preclinical data indicate that AV-951 blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo. Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients. AV-951(Tivozanib) is under early clinical investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients.
Tivozanib(AV-951)

Synonyms: Tivozanib(AV-951)CAS NO: 475108-18-0Molecular Formula: C₂₂H₁₉ClN₄O₅Molecular Weight: 454.86Purity: 99%Solubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com